Approval · Notice of Compliance 37356 · 2026
REACTINE 20 MG TABLET: Notice of Compliance 37356
Issued April 17, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 37356
- Date
- April 17, 2026
- Company
- Kenvue Canada Inc.Guelph, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- Administrative: Change in manufacturer name
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| REACTINE 20 MG TABLET | 01900978 | Marketed |
Medicinal ingredients
- CETIRIZINE HYDROCHLORIDE 20 MG per TAB